TGF-β1 (Transforming Growth Factor Beta 1) is a multifunctional cytokine that plays critical roles in regulating inflammation, tissue repair, and neuroprotection in the central nervous system. As one of the most important anti-inflammatory cytokines, TGF-β1 exerts complex effects on neuronal survival, astrocyte function, microglial activation, and immune cell behavior. This page provides comprehensive information about TGF-β1 structure, signaling mechanisms, normal CNS functions, and its dual roles in neurodegenerative diseases.
--- [1]
title: TGF-β1 Protein [2]
description: TGF-β1 Transforming Growth Factor Beta-1 - Anti-inflammatory cytokine in neuroprotection and neurodegeneration [3]
--- [4]
| | | [5]
|---|---| [6]
| Protein Name | Transforming Growth Factor Beta-1 (TGF-β1) | [7]
| Gene | TGFB1 | [8]
| UniProt ID | P01137 |
| PDB ID | 3KFD, 1TGF, 2PJY |
| Molecular Weight | 25 kDa (latent), 12.5 kDa (active) |
| Amino Acids | 390 (prepro), 112 (mature) |
| Structure | Cysteine knot growth factor fold |
| Chromosome | 19q13.2 |
TGF-β1 is a member of the TGF-β superfamily (which includes TGF-β1, TGF-β2, TGF-β3, bone morphogenetic proteins, and others). It is synthesized as a preproprotein that undergoes proteolytic processing to generate the mature active cytokine. TGF-β1 is secreted in a latent form (LAP - Latency-Associated Peptide) and must be activated to signal.
In the CNS, TGF-β1 is produced by neurons, astrocytes, microglia, and infiltrating immune cells. It regulates:
TGF-β1 is synthesized as a 390-amino acid preproprotein:
TGF-β1 undergoes complex post-translational processing:
LTBP-1 binds the latent TGF-β1 complex:
The mature TGF-β1 adopts a cysteine knot fold:
TGF-β signals through receptor serine/threonine kinases:
Type I Receptors (ALK5/TβRI):
Type II Receptors (TβRII):
Type III Receptors (Betaglycan):
R-Smads:
Common Smad:
TGF-β also activates:
Smad complexes regulate gene expression:
Oligodendrocytes:
TGF-β1 has complex, often beneficial roles in AD:
Expression patterns:
Protective mechanisms:
Potentially harmful effects:
Therapeutic implications:
In PD, TGF-β1 has neuroprotective potential:
Expression patterns:
Protective mechanisms:
Therapeutic implications:
TGF-β1 plays complex roles in ALS:
Expression patterns:
Mechanisms:
Therapeutic implications:
In MS, TGF-β1 has regulatory roles:
Expression patterns:
Mechanisms:
Therapeutic implications:
| Agent | Mechanism | Status |
|---|---|---|
| Recombinant TGF-β1 | Direct ligand | Preclinical |
| AAV-TGFβ1 | Gene therapy | Preclinical |
| Smad7 siRNA | Reduce inhibition | Research |
| Integrin agonists | Enhance activation | Research |
Used in conditions of excessive fibrosis:
| Agent | Mechanism | Status |
|---|---|---|
| Fresolimumab | Anti-TGF-β antibody | Clinical trials |
| LY2109761 | TβRI/II inhibitor | Cancer trials |
| SMAD7 gene therapy | Decoy | Research |
TGFB1 polymorphisms affect disease risk:
TGF-β1 as a biomarker:
TGF-β1 is a critical anti-inflammatory cytokine with complex roles in neurodegeneration. It generally promotes neuronal survival, modulates glial function, and suppresses harmful neuroinflammation, making it an attractive therapeutic target. However, its pleiotropic nature and potential for fibrosis require careful approach. Enhancing TGF-β1 signaling in the CNS represents a promising strategy for AD, PD, and ALS, though significant challenges remain in achieving targeted delivery and appropriate dosing.
The study of Tgf Β1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Krieglstein K, et al. TGF-β in nervous system development and function. Cell Tissue Res. 2012. ↩︎
Tesseur I, et al. TGF-β1 deficiency in the brain leads to neuroinflammation and memory deficits. J Neurosci. 2006. ↩︎
Chen JH, et al. TGF-β1 in Alzheimer's disease and Parkinson's disease. Neurobiol Dis. 2020. ↩︎
von Bernhardi R, et al. TGF-β1 in neurodegeneration: friend or foe? Mol Neurobiol. Mol Neurobiol. 2015. ↩︎
Wyss-Coray T, et al. TGF-β1 in brain aging and neurodegeneration. Nat Rev Neurosci. 2003. ↩︎
Tatenhorst L, et al. AAV-mediated TGF-β1 gene therapy for Parkinson's disease. Mol Ther. 2016. ↩︎
Qian C, et al. Astrocyte TGF-β signaling in neurodegeneration. Neurochem Int. 2018. ↩︎
Makwana R, et al. TGF-β in multiple sclerosis and its animal model EAE. J Neuroimmunol. 2010. ↩︎